ArticleLiver cancer2019
Pembrolizumab for the Treatment of Hepatocellular Carcinoma.
Article in Liver cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Review
- Interactions between tumor microenvironment and resistance to transarterial and systemic treatments for HCC.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Development of an LC-TOF/MS Method to Quantify Camrelizumab in Human Serum.Molecules (Basel, Switzerland) · 2024Article
- Review
- Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future.Journal of clinical and translational hepatology · 2024Review
- A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma.Journal of liver cancer · 2023Article
- Review
- A change point-based analysis procedure for improving the success rate of decision-making in clinical trials with delayed treatment effects.Frontiers in pharmacology · 2023Article
- Review
- Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study.Frontiers in oncology · 2022Article
- Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.Journal of clinical medicine · 2021Review
- Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma.Oncology letters · 2021Review
- Combination immunotherapy with anti-VEGF/TKI for hepatocellular carcinoma: present and future perspective.Hepatobiliary surgery and nutrition · 2021Article
- Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.Frontiers in immunology · 2021Review
- Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.Liver cancer · 2020Article
- Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy.Cancer medicine · 2020Article
- Review
- A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.Liver cancer · 2020Article
- Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?Immune network · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.